Browse

Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer

DC Field Value Language
dc.contributor.authorNam, Hyun-Jin-
dc.contributor.authorKim, Hwang-Phill-
dc.contributor.authorYoon, Young-Kwang-
dc.contributor.authorHur, Hyung-Seok-
dc.contributor.authorSong, Sang-Hyun-
dc.contributor.authorKim, Maeng-Sup-
dc.contributor.authorLee, Gwan-Sun-
dc.contributor.authorHan, Sae-Won-
dc.contributor.authorIm, Seock-Ah-
dc.contributor.authorKim, Tae-You-
dc.contributor.authorOh, Do-Youn-
dc.contributor.authorBang, Yung-Jue-
dc.date.accessioned2021-01-31T11:00:35Z-
dc.date.available2021-01-31T11:00:35Z-
dc.date.issued2011-03-
dc.identifier.citationCancer Letters, Vol.302 No.2, pp.155-165-
dc.identifier.issn0304-3835-
dc.identifier.other119682-
dc.identifier.urihttps://hdl.handle.net/10371/172959-
dc.description.abstractTrastuzumab, a HER2 directed treatment has shown clinical benefit in HER2 amplified gastric cancer. This study demonstrated the potent antitumor activity of HM781-36B, a quinazoline-based irreversible pan-HER inhibitor, in HER2 amplified gastric cancer cells (SNU216 and N87) in vitro and in vivo. HM781-36B inhibited phosphorylation of HER family and downstream signaling molecules, and induced apoptosis and G1 arrest. Furthermore, HM781-36B exerted synergistic effects with chemotherapeutic agents in both HER2 amplified and HER2 non-amplified gastric cancer cells. Therefore, HM781-36B may be useful for the treatment of HER2 amplified gastric cancer alone or in combination with chemotherapeutic agents. (C) 2011 Elsevier Ireland Ltd. All rights reserved.-
dc.subjectHM781-36B-
dc.subjectPan-HER inhibitor-
dc.subjectGastric cancer-
dc.subjectAntitumor activity-
dc.subjectChemotherapeutic agents-
dc.titleAntitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer-
dc.typeArticle-
dc.contributor.AlternativeAuthor방영주-
dc.identifier.doi10.1016/j.canlet.2011.01.010-
dc.citation.journaltitleCancer Letters-
dc.identifier.scopusid2-s2.0-79951580512-
dc.citation.endpage165-
dc.citation.number2-
dc.citation.startpage155-
dc.citation.volume302-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0304383511000231?via%3Dihub-
dc.identifier.rimsid119682-
dc.identifier.sci000288357300010-
dc.contributor.affiliatedAuthorBang, Yung-Jue-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse